⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213201 | 1.00 | — | — | |
| SCHEMBL3303200 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4726636 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL14941148 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL14941350 | 0.98 | — | — | |
| SCHEMBL2070019 | 0.93 | — | — | |
| SCHEMBL13950271 | 0.93 | — | — | |
| SCHEMBL7504697 | 0.93 | CPN1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL22691392 | 0.91 | CPN1 (0.40) | — | |
| SCHEMBL6066303 | 0.86 | CPN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-120192324-A | Heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025064535-A1 | TRICYCLIC SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040102482-A1 | Antibacterial Mutilins | Nabriva Therapeutics GmbH (AT) | 2004-05-27 | — | — | US | disclosed |
| EP-1320525-B1 | ANTIBACTERIAL MUTILINS | BIOCHEMIE GMBH (AT) | 2004-04-21 | — | — | EP | disclosed |
| EP-1320525-A1 | ANTIBACTERIAL MUTILINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-06-25 | — | — | EP | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002022580-A1 | ANTIBACTERIALS MUTILINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-03-21 | — | — | WO | disclosed |
| CN-1306511-A | Novel heterocyclic compounds | NOVO NORDISK AS (DK) | 2001-08-01 | — | — | CN | disclosed |
| US-4481207-A | CALCIUM ANTAGONISTS, HYPOTENSIVES | SYNTHELABO (FR) | 1984-11-06 | — | — | US | disclosed |